Drug Manufacturer Recalls Simvastatin Tablets for Manufacturing Deviations
Direct Rx recalled Simvastatin 10 mg tablets nationwide due to manufacturing process deviations discovered during production. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries and manufacturing process deviations. This voluntary, firm-initiated precautionary recall falls under the Moderate category per the rubric criteria for voluntary recalls without reported harm.
Plain-English summary
Direct Rx is recalling Simvastatin, USP 10 mg tablets that were distributed nationwide. The medication is available in 30-count and 90-count bottles under FDA approval as a prescription-only drug.
The recall was initiated voluntarily by Direct Rx due to cGMP deviations—manufacturing process violations related to current Good Manufacturing Practice standards. These standards ensure the quality and safety of pharmaceutical manufacturing.
Patients in possession of affected bottles should contact their pharmacy or healthcare provider to verify if their medication is part of the recall using the lot and expiration date information. No illnesses or injuries have been reported in connection with this product. The FDA classified this as a Class II recall.
The recalled product
- Product
- Simvastatin, USP, 10 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0688-30 b) 90-count bottle, NDC61919-0688-90, Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534
- Manufacturer
- Direct Rx
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- a) [30-count bottles] Lot
- expiry: 05AU2206
- exp 10/31/23
- b) [90-count bottles] Lot
- expiry: 30MA2213
- exp 6/30/23
- 10DE2124
- exp 3/31/23
- 15MA2224
- exp 5/32/23
- 27JA2229
- exp 3/31/23.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27